The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, is a group of clinical trials for patients with certain types of early-stage non-small cell lung cancers (NSCLC) that have been treated surgically. The ALCHEMIST trials involve genetic screening of tumor specimens for specific gene mutations (EGFR and ALK)  and testing of adjuvant (post-operative) treatment with drugs approved by the FDA for use in targeting those mutations in advanced lung cancer. All patients, regardless of assignment to the list of treatment arms, participate in large scale genomic analysis on a research basis through the Center for Cancer Genomics (CCG).

The ALCHEMIST studies are being coordinated by the Alliance for Clinical Trials in Oncology and the ECOG-ACRIN Cancer Research Group, members of the NCI-sponsored National Clinical Trials Network (NCTN), as part of the institute’s national strategy for precision medicine.

The BCR is responsible for the collection and processing of specimens for the ALCHEMIST A151216 project.  After specimens qualify by pathology and molecular metrics at the BCR, molecular analytes are then distributed to characterization centers. Once qualified, patients will be enrolled in the A151216 long-term follow-up study.

For questions about this trial or for more information about lung cancer, please call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Click here to visit the National Cancer Institute's Questions and Answers page for ALCHEMIST.

Click here to visit the National Cancer Institute’s website for more details on the ALCHEMIST A151216 trial.